Recent studies have highlighted the significant potential of TCMFG in treating complex diseases, such as inflammation, tumors, metabolic disorders, fibrosis, and orthopedic conditions like osteoarthritis and osteoporosis, by modulating signaling pathways such as TLR4/NF-κB, MAPK, NLRP3 inflammasome, PI3K/Akt/mTOR, Wnt/β-catenin, and TGF-β/Smads. The gene discussed is AKT1; the disease is metabolic disease.